Expertise in
13
conditions

Michael L. Friedlander

Barker St, 
Randwick, NSW, AU 
Expertise in
13
conditions
Barker St, 
Randwick, NSW, AU 

Overview

Michael Friedlander practices practicing medicine in Randwick, Australia.

Mr. Friedlander is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Breast Cancer, Endometrial Cancer, Oophorectomy, and Salpingo-Oophorectomy.

He is actively involved in clinical research, co-authoring 309 peer reviewed articles and participating in 4 clinical trials.

Gender

Male

Locations

Barker St, Randwick, NSW 2031, Australia
Other Locations
High Street, Randwick, NSW 2031, Australia

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors
A Phase 1b, Open-Label, Dose-escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of a RAF Dimer Inhibitor BGB-283 in Combination With MEK Inhibitor PD-0325901 in Patients With Advanced or Refractory Solid Tumors
Enrollment Status: Completed
Publish Date: January 07, 2026
Intervention Type: Drug
Study Phase: Phase 1
A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours
A Retrospective/Prospective Analysis of Characterization of the Long-Term Responders on Olaparib in Solid Tumours
Enrollment Status: Completed
Publish Date: January 10, 2023
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
A Phase 2 Study of Prexasertib in Platinum-Resistant or Refractory Recurrent Ovarian Cancer
Enrollment Status: Completed
Publish Date: August 19, 2022
Intervention Type: Drug
Study Drug: Prexasertib
Study Phase: Phase 2
A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion
A Phase II, Signal-Seeking Trial of the Clinical Benefit Rate Associated With Pamiparib in Subjects With Germline or Somatic BRCA1/2 High Grade Serous Ovarian Cancer or Carcinosarcoma Who Have Progressed on P-gp Substrate Chemotherapy or PARPi With the Presence of an ABCB1 Fusion and the Absence of a BRCA1/2 Reversion
Enrollment Status: Withdrawn
Publish Date: August 10, 2021
Intervention Type: Drug
Study Drug: Pamiparib
Study Phase: Phase 2
View 3 Less Clinical Trials

307 Total Publications

Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.
Enhancing Outcome Measurement in Oncology Clinical Trials Through Artificial Intelligence: A Scoping Review.
Journal: JCO clinical cancer informatics
Published: July 10, 2026

Frequently Asked Questions about Michael L. Friedlander

Is Michael L. Friedlander a top-rated expert for Ovarian Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Michael L. Friedlander is classified as an Elite expert for Ovarian Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Michael L. Friedlander participate in research or clinical trials?

Yes. Michael L. Friedlander has published 307 articles and abstracts on conditions like Ovarian Cancer. You can view a list of Michael L. Friedlander's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Friedlander's expertise for a condition
ConditionClose
View All 11 Advanced Conditions
View All 15 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile